Personalis (PSNL) Aandelenoverzicht
Personalis, Inc. ontwikkelt, verkoopt en verhandelt geavanceerde genomische kankertests en -diensten in de Verenigde Staten en daarbuiten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
PSNL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Personalis, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$14.50 |
| 52 Week Hoogtepunt | US$16.39 |
| 52 Week Laag | US$4.42 |
| Bèta | 2.28 |
| 1 maand verandering | 3.06% |
| 3 maanden verandering | 140.07% |
| 1 Jaar Verandering | 222.22% |
| 3 jaar verandering | 667.20% |
| 5 jaar verandering | -18.45% |
| Verandering sinds IPO | -49.10% |
Recent nieuws en updates
Narratiefupdate • Aug 07
PSNL: Tempus Deal And MRD Franchise Will Reprice Future Risk Reward
Analysts have lifted their fair value estimate for Personalis, with the price target moving from $13.00 to $16.25 as they factor in the agreed all stock acquisition by Tempus AI at $16.25 per share and the perceived fit of Personalis' MRD franchise within Tempus AI's precision oncology portfolio. Analyst Commentary Recent commentary on Personalis following the Tempus AI all stock acquisition agreement has leaned constructive, with several bullish analysts highlighting both the agreed transaction value of $16.25 per share and the fit of Personalis' MRD assets within a larger precision oncology platform.
Narratiefupdate • Jul 24
PSNL: Pending Tempus Acquisition And MRD Milestones Will Support Future Upside
Analysts lifted their price target for Personalis from $10.86 to $13.88, citing the agreed $16.25 per share all-stock acquisition by Tempus AI and the view that the deal terms now anchor valuation expectations. Analyst Commentary Recent research on Personalis clusters around the Tempus AI all stock acquisition, with analysts focusing on how the agreed US$16.25 per share deal shapes valuation, execution risk, and future growth ambitions for the combined company.Seeking Alpha • Jul 21
Personalis: Tempus Bought The Best Part Of The Story
Summary Personalis reached a commercial inflection with accelerating clinical adoption, expanding Medicare reimbursement, and its differentiated MRD platform gaining traction. The Tempus AI all-stock acquisition at a modest 6% premium shifts PSNL from a standalone growth story to a derivative of TEM's share price. Despite strong operational momentum, PSNL shareholders now face capped upside and opportunity cost, as future value accrues to Tempus post-acquisition. I assign PSNL a Sell rating not due to business weakness, but because the investment thesis is now tied to waiting for Tempus shares. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • Aug 07
PSNL: Tempus Deal And MRD Franchise Will Reprice Future Risk Reward
Analysts have lifted their fair value estimate for Personalis, with the price target moving from $13.00 to $16.25 as they factor in the agreed all stock acquisition by Tempus AI at $16.25 per share and the perceived fit of Personalis' MRD franchise within Tempus AI's precision oncology portfolio. Analyst Commentary Recent commentary on Personalis following the Tempus AI all stock acquisition agreement has leaned constructive, with several bullish analysts highlighting both the agreed transaction value of $16.25 per share and the fit of Personalis' MRD assets within a larger precision oncology platform.Narratiefupdate • Jul 24
PSNL: Pending Tempus Acquisition And MRD Milestones Will Support Future Upside
Analysts lifted their price target for Personalis from $10.86 to $13.88, citing the agreed $16.25 per share all-stock acquisition by Tempus AI and the view that the deal terms now anchor valuation expectations. Analyst Commentary Recent research on Personalis clusters around the Tempus AI all stock acquisition, with analysts focusing on how the agreed US$16.25 per share deal shapes valuation, execution risk, and future growth ambitions for the combined company.Seeking Alpha • Jul 21
Personalis: Tempus Bought The Best Part Of The Story
Summary Personalis reached a commercial inflection with accelerating clinical adoption, expanding Medicare reimbursement, and its differentiated MRD platform gaining traction. The Tempus AI all-stock acquisition at a modest 6% premium shifts PSNL from a standalone growth story to a derivative of TEM's share price. Despite strong operational momentum, PSNL shareholders now face capped upside and opportunity cost, as future value accrues to Tempus post-acquisition. I assign PSNL a Sell rating not due to business weakness, but because the investment thesis is now tied to waiting for Tempus shares. Read the full article on Seeking Alpha
Narratiefupdate • Jul 10
PSNL: Ongoing Clinical Spending And Equity Offering Will Pressure Longer Term Upside
Analysts have increased the fair value estimate for Personalis from $9.00 to $10.00, citing updated models and a higher price target of $13.00 as they refine expectations ahead of upcoming earnings. Analyst Commentary Recent research updates on Personalis show a mix of optimism and caution as analysts adjust their models ahead of upcoming earnings.Narratiefupdate • Jun 19
PSNL: Recent Coverage, Clinical Progress And Losses Will Shape Longer Term Upside
Analysts have reduced their price targets on Personalis stock by about $1 to $2, citing updated fair value estimates near $9.00, an adjusted discount rate, and refreshed assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary on Personalis Stock Recent research updates around Personalis reflect a more cautious tone, with price targets trimmed by about $1 to $2 as bearish analysts reassess valuation and execution risks.Analyse-artikel • Jun 16
Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data
Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...Narratiefupdate • Jun 04
PSNL: Ultrasensitive MRD Evidence And Expanded Coverage Will Support Balanced Future Outlook
Analysts have trimmed their price targets on Personalis by $1 to $2, citing updated assumptions for discount rates, profit margins, and long term P/E expectations. These revisions result in a slightly lower overall valuation outlook.Narratiefupdate • May 21
PSNL: Expanded Coverage And MRD Evidence Will Underpin Future Upside Potential
Analysts have nudged their average price target for Personalis lower by about $0.40. This reflects updated forecasts that factor in higher projected net losses and operating expenses in later years.Narratiefupdate • May 01
PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential
Analysts have trimmed their price target on Personalis to $10 from $11, citing updated views on longer term operating expenses and expected net losses. These updates also feed into a slightly higher discount rate and future P/E assumptions in current models.Narratiefupdate • Apr 16
PSNL: Higher Spending And 2026 Loss Will Set Up Longer Term Upside Potential
Analysts now converge around a $10 price target for Personalis, reflecting updated views that incorporate expectations for higher outer year operating expenses and a wider 2026 net loss. Analyst Commentary Recent research updates point to a more cautious tone around Personalis, particularly as analysts factor in guidance for higher operating expenses and a wider 2026 net loss.Narratiefupdate • Apr 02
PSNL: Expanded Clinical Evidence And Coverage Will Support A Stronger Long Term Outlook
Analysts now center on a $10 price target for Personalis, citing updated loss expectations and higher longer term operating expense assumptions as key drivers of the shift from prior Street estimates. Analyst Commentary Bearish analysts are resetting expectations around Personalis, using the new $10 price target as a reference point for what they see as a more cautious risk and reward profile.Narratiefupdate • Mar 19
PSNL: Medicare Coverage And MRD Data Will Reprice Future Risk Reward
Analysts have adjusted their view on Personalis, with price targets now ranging between $10 and $11 as they factor in updated expectations for future losses and operating expenses. Analyst Commentary Recent research updates on Personalis highlight a mix of cautious modeling changes and ongoing interest in the company’s longer term potential.Narratiefupdate • Mar 05
PSNL: Medicare Coverage Will Support Future Risk Reward Repricing
Narrative Update on Personalis The analyst price target on Personalis has moved from $13 to $13.00 as analysts factor in updated assumptions around revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish analysts have adjusted their price targets on Personalis, with one recent move taking the target to $13.00.Narratiefupdate • Feb 18
PSNL: Medicare Coverage And Refined Assumptions Will Support A Brighter Outlook
Analysts have increased their price target on Personalis by $1, citing updated views on fair value, slightly revised discount rate assumptions, and refreshed expectations for revenue growth, profit margin, and future P/E. Analyst Commentary Although the latest research includes a higher price target for Personalis, the tone around the stock remains measured.Narratiefupdate • Feb 04
PSNL: Medicare Coverage For Cancer Surveillance Will Reshape Future Risk Reward Profile
Analysts have increased their fair value estimate for Personalis from US$9.00 to US$13.00, citing updated assumptions around revenue growth, profit margins, and future P/E. They have also incorporated recent Street research that reflected Medicare coverage news and refreshed price targets.Narratiefupdate • Jan 21
PSNL: Medicare Coverage Will Shape Future Upside Despite Biopharma Headwinds
Narrative update on Personalis Analysts have lifted their blended price expectations for Personalis toward the US$9 to US$11 range, citing recent Medicare coverage for the NeXT Personal test and Q3 revenue that came in above guidance as key supports for the higher targets. Analyst Commentary Recent Street research on Personalis has focused on two main developments: Medicare coverage for the NeXT Personal test in breast cancer surveillance, and Q3 revenue that came in ahead of the guided range, internal estimates, and consensus.Analyse-artikel • Jan 17
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a really impressive month, gaining 28% after a shaky period...Narratiefupdate • Jan 07
PSNL: Medicare Coverage And Biopharma Headwinds Will Shape A Balanced Outlook
Analysts lifted their projected fair value for Personalis, citing recent price target increases to $9 and $11, and pointing to Medicare coverage for the NeXT Personal test and reimbursement trends as key supports for their updated view. Analyst Commentary Recent research takes a mixed view on Personalis, with price targets being adjusted around specific catalysts such as Medicare coverage for NeXT Personal and reported Q3 revenue.Narratiefupdate • Dec 23
PSNL: Medicare Coverage Will Drive Reimbursement Momentum And Support A Higher Share Price
Analysts have raised their price target on Personalis significantly, from about $5 to a range centered near $10 per share, citing stronger revenue growth expectations, improving profit margins, and increased confidence in long-term reimbursement trends. Analyst Commentary Recent target price revisions reflect a more constructive outlook on Personalis as reimbursement visibility improves and revenue trends modestly outperform prior expectations.Narratiefupdate • Dec 09
PSNL: Medicare Reimbursement Will Drive Future Momentum Despite Biopharma Guidance Headwinds
Analysts have modestly raised their price target on Personalis, citing stronger-than-expected Q3 revenue and expanding reimbursement visibility. Their estimate of fair value has edged up from roughly $10.71 to $11.00 per share.Narratiefupdate • Nov 24
PSNL: Medicare Coverage Will Support Momentum Despite Guidance Headwinds
Narrative Update on Personalis Analysts have raised their price target for Personalis from approximately $8.50 to $10.71 per share. They cite recent Medicare coverage for the NeXT Personal test and stronger-than-expected quarterly revenue as supporting factors for the upward revision.Narratiefupdate • Nov 08
PSNL: Reimbursement Progress Will Drive Momentum Despite Guidance Reduction
Analysts have raised their fair value estimate for Personalis from $8.06 to $8.50 per share. They cite stronger revenue growth prospects and continued progress on reimbursement as key factors behind the upgrade.Analyse-artikel • Nov 07
Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50
Personalis, Inc. ( NASDAQ:PSNL ) just released its quarterly report and things are looking bullish. Revenues beat...Analyse-artikel • Oct 31
Personalis, Inc.'s (NASDAQ:PSNL) P/S Is Still On The Mark Following 46% Share Price Bounce
Despite an already strong run, Personalis, Inc. ( NASDAQ:PSNL ) shares have been powering on, with a gain of 46% in the...Narratiefupdate • Oct 25
Clinical Testing Progress And Medicare Coverage Will Influence Share Momentum Ahead
Analysts have revised Personalis's price target downward from $8.00 to $6.00. They cite weaker than expected pharma order timing and softer profit projections, despite continued progress in clinical testing and Medicare coverage goals.Analyse-artikel • Sep 16
Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analyse-artikel • Sep 10
Is Personalis (NASDAQ:PSNL) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Aug 10
These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat
Today is shaping up negative for Personalis, Inc. ( NASDAQ:PSNL ) shareholders, with the analysts delivering a...Analyse-artikel • Aug 02
Personalis, Inc. (NASDAQ:PSNL) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
The Personalis, Inc. ( NASDAQ:PSNL ) share price has softened a substantial 28% over the previous 30 days, handing back...Analyse-artikel • May 06
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 37% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 37% in the...
Nieuw narratief • Mar 30
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.Analyse-artikel • Mar 21
What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Personalis, Inc. ( NASDAQ:PSNL ) shareholders that were waiting for something to happen have been dealt a blow with a...Analyse-artikel • Mar 02
Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for Personalis, Inc. ( NASDAQ:PSNL ), who've watched their investment drop 12% to US$4.14 in the...Analyse-artikel • Feb 04
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 26% after a relatively good period...Analyse-artikel • Nov 19
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Personalis, Inc. ( NASDAQ:PSNL ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 28
The Proper Play On Personalis
Summary Today, we revisit the diagnostic concern of Personalis, Inc. The company recently expanded its partnership with Tempus AI and is seeing lower quarterly losses. The company has a solid balance sheet, strong analyst support, and is seeing revenue growth in a large and growing market. An updated analysis around Personalis follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Sep 14
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Personalis, Inc. ( NASDAQ:PSNL ) shares have continued their recent momentum with a 28% gain in the last month alone...Analyse-artikel • Jul 25
A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Personalis, Inc. ( NASDAQ:PSNL ) shareholders have had their patience rewarded with a 131% share price jump in the last...Analyse-artikel • Apr 19
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 25% after a relatively good period...Analyse-artikel • Mar 02
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Personalis, Inc. ( NASDAQ:PSNL ) shareholders would be excited to see that the share price has had a great month...Rendement voor aandeelhouders
| PSNL | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 9.8% | 5.0% | 2.2% |
| 1Y | 222.2% | 27.6% | 20.9% |
Rendement versus industrie: PSNL overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 27.6 % opleverde.
Rendement versus markt: PSNL overtrof de US markt, die het afgelopen jaar een rendement opleverde van 20.9 %.
Prijsvolatiliteit
| PSNL volatility | |
|---|---|
| PSNL Average Weekly Movement | 12.2% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: De aandelenkoers van PSNL is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van PSNL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2011 | 260 | Chris Hall | www.personalis.com |
Personalis, Inc. ontwikkelt, verkoopt en verkoopt geavanceerde genomische kankertests en -diensten in de Verenigde Staten en daarbuiten. Het bedrijf biedt NeXT Personal, een vloeibare biopsietest op basis van de tumor voor de detectie van minimale restziekte (MRD), therapierespons en recidiefmonitoring bij solide tumorkankers; en ImmunoID NeXT, een weefselgebaseerde service die whole exome en whole transcriptome sequencing-gegevens combineert met geavanceerde analyses om een multidimensionaal beeld te geven van de tumor en de tumormicro-omgeving op basis van één enkel monster. Het bedrijf levert ook NeXT Personal Dx, een vloeibare biopsietest op basis van de tumor voor de detectie van MRD; en NeXT Dx, een test voor tumorprofilering die wordt gebruikt om te helpen bij de therapiekeuze voor een kankerpatiënt en om potentiële klinische proeven voor een patiënt te identificeren.
Personalis, Inc. Samenvatting
| PSNL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.51b |
| Inkomsten(TTM) | -US$107.18m |
| Inkomsten(TTM) | US$69.67m |
22.2x
P/S-verhouding-14.4x
Koers/WinstverhoudingIs PSNL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| PSNL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$69.67m |
| Kosten van inkomsten | US$60.83m |
| Brutowinst | US$8.84m |
| Overige uitgaven | US$116.02m |
| Inkomsten | -US$107.18m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.00 |
| Brutomarge | 12.69% |
| Nettowinstmarge | -153.84% |
| Schuld/Eigen Vermogen Verhouding | 0.4% |
Hoe presteerde PSNL op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/10 16:43 |
| Aandelenkoers aan het einde van de dag | 2026/08/10 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Personalis, Inc. wordt gevolgd door 13 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |